June 17, 2024
5 min watch
Save
VIDEO: Belantamab mafodotin ‘comeback kid’ for relapsed refractory multiple myeloma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.
A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did not meet the primary endpoint.
“But now, this is a comeback kid,” said Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center.
He also highlighted a subgroup analysis of when to best treat patients with relapsed refractory multiple myeloma with chimeric antigen receptor T-cell therapy.
References:
- Mateos MV, et al. Abstract 7503. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
- Trudel S, et al. Abstract LBA105. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Fung reports serving on the speakers’ bureau of AstraZeneca, Incyte and Johnson and Johnson.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.